Spyre Therapeutics, Inc.SYRE
What Spyre Therapeutics, Inc. does.
Spyre Therapeutics, Inc. (NASDAQ: SYRE) is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre’s pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations.
Our goal is to develop next-generation therapeutics to redefine the standard of care for the treatment of IBD and other immune-mediated diseases, relying on three strategic pillars:
• Advancing a portfolio of next-generation monotherapies - novel antibody candidates engineered for optimized potency, selectivity, and pharmacokinetics ("PK") against validated IBD targets
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $18.7M | $2.3M | $886,000 | $0 | $0 |
| Net income | -$80.9M | -$65.8M | -$83.8M | -$338.8M | -$208.0M | -$155.2M |
| Free cash flow | -$80.1M | -$54.3M | -$80.2M | -$99.9M | -$157.4M | — |
More on SYRE.
- Spyre Therapeutics, Inc. summary
- Spyre Therapeutics, Inc. financial statements
- Spyre Therapeutics, Inc. key metrics
- Spyre Therapeutics, Inc. health scores and style box
- Spyre Therapeutics, Inc. earnings
- Spyre Therapeutics, Inc. dividends
- Spyre Therapeutics, Inc. valuation
- Spyre Therapeutics, Inc. ownership and insiders
- Spyre Therapeutics, Inc. peers
Figures from Spyre Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.